Tags

Type your tag names separated by a space and hit enter

A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season.
Vaccine. 2012 Sep 14; 30(42):6099-102.V

Abstract

The 2007 US approval for use of Ann Arbor strain live attenuated influenza vaccine (LAIV) in children aged 24 through 59 months included precautions against use in (1) children <24 months and children aged 24 through 59 months with (2) asthma, (3) recurrent wheezing, and (4) altered immunocompetence. Results from the third season (2009-2010) of a 3-year study postmarketing commitment to monitor LAIV vaccination rates and frequency of hospitalizations or emergency department visits within 42 days after LAIV are reported here. As in the first 2 seasons, LAIV usage in cohorts 1, 2, and 4 were low relative to those in LAIV-recommended populations. The only numerically increased risk observed was for respiratory events in children aged <24 months administered LAIV, compared to those administered trivalent inactivated influenza vaccine (TIV). The number of children vaccinated with LAIV was small and precluded precise quantification of rare event.

Authors+Show Affiliations

RTI Health Solutions, 3040 Cornwallis Road, Post Office Box 12194, Research Triangle Park, NC 27709, USA. ptennis@rti.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22841479

Citation

Tennis, Patricia, et al. "A US Postmarketing Evaluation of the Frequency and Safety of Live Attenuated Influenza Vaccine Use in Nonrecommended Children Younger Than 5 Years: 2009-2010 Season." Vaccine, vol. 30, no. 42, 2012, pp. 6099-102.
Tennis P, Toback SL, Andrews EB, et al. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season. Vaccine. 2012;30(42):6099-102.
Tennis, P., Toback, S. L., Andrews, E. B., McQuay, L. J., & Ambrose, C. S. (2012). A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season. Vaccine, 30(42), 6099-102. https://doi.org/10.1016/j.vaccine.2012.07.031
Tennis P, et al. A US Postmarketing Evaluation of the Frequency and Safety of Live Attenuated Influenza Vaccine Use in Nonrecommended Children Younger Than 5 Years: 2009-2010 Season. Vaccine. 2012 Sep 14;30(42):6099-102. PubMed PMID: 22841479.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season. AU - Tennis,Patricia, AU - Toback,Seth L, AU - Andrews,Elizabeth B, AU - McQuay,Lisa J, AU - Ambrose,Christopher S, Y1 - 2012/07/25/ PY - 2012/05/25/received PY - 2012/07/12/revised PY - 2012/07/13/accepted PY - 2012/7/31/entrez PY - 2012/7/31/pubmed PY - 2013/1/8/medline SP - 6099 EP - 102 JF - Vaccine JO - Vaccine VL - 30 IS - 42 N2 - The 2007 US approval for use of Ann Arbor strain live attenuated influenza vaccine (LAIV) in children aged 24 through 59 months included precautions against use in (1) children <24 months and children aged 24 through 59 months with (2) asthma, (3) recurrent wheezing, and (4) altered immunocompetence. Results from the third season (2009-2010) of a 3-year study postmarketing commitment to monitor LAIV vaccination rates and frequency of hospitalizations or emergency department visits within 42 days after LAIV are reported here. As in the first 2 seasons, LAIV usage in cohorts 1, 2, and 4 were low relative to those in LAIV-recommended populations. The only numerically increased risk observed was for respiratory events in children aged <24 months administered LAIV, compared to those administered trivalent inactivated influenza vaccine (TIV). The number of children vaccinated with LAIV was small and precluded precise quantification of rare event. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22841479/A_US_postmarketing_evaluation_of_the_frequency_and_safety_of_live_attenuated_influenza_vaccine_use_in_nonrecommended_children_younger_than_5_years:_2009_2010_season_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(12)01044-4 DB - PRIME DP - Unbound Medicine ER -